Counsel: Consider the pitfalls before relisting in Hong Kong

0
2460

Chinese companies taken private in the US may consider relisting in Hong Kong as an attractive option, but beware the pitfalls, legal experts involved in the recent WuXi Biologics’ relisting in Hong Kong have warned.

罗德源 COLIN LAW
罗德源
COLIN LAW

WuXi Biologics recently completed its US$510 million global offering and initial public offering (IPO) on the Main Board of the Stock Exchange of Hong Kong, marking the second Chinese company to relist in Hong Kong after going private in the US.

Compared with re-listing in mainland China, one of the major attractions of Hong Kong is the certainty on timing and procedural transparency, Paloma Wang, Hong Kong capital markets partner at Shearman & Sterling, told China Business Law Journal.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们